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Reporting in a recent issue of Neuron, Yamada et al. (2014) show that the histone deacetylase (HDAC)-
containing NuRD complex plays a critical role in shutting down expression of specific synaptogenesis-
related genes in the cerebellum, resulting in enhanced differentiation of presynaptic structures. This work
suggests that HDACs in neurons acquire specificity through NuRD.The brain is the essential control center for
mammalian sensory, motor, autonomic,
emotion, and cognitive functions. It elicits
experience-based adaptive responses,
such as learning and memory, and
accomplishes many of these tasks using
epigenetic mechanisms. Therefore, it is
highly enriched for many epigenetic
machineries, including DNA and histone
modification factors, chromatin remodel-
ing complexes, and noncoding regulatory
RNAs, many of which have been shown to
play pivotal roles in brain development,
plasticity of neural circuitry functions,
and pathoetiologies of neurological disor-
ders (Portela and Esteller, 2010; Sweatt
et al., 2013).
It is commonly believed that acetylated
histones are associated with more loose
and open chromatin structures that are
amenable to transcriptional activation. In
contrast, histone deacetylation is often
associated with transcription inactiva-
tion (Martin and Sun, 2004). With this
in mind, histone deacetylases (HDACs)
have been considered and tested as tar-
gets for therapeutic interventions for can-
cer as well as neurological diseases.
However, because HDACs appear to
have global action within the whole
genome, it remains a puzzle as to how
HDACs render specificity to make them
useful targets for diseases affecting spe-
cific organs such as the brain.
HDACs associate with other proteins to
form stable complexes, such as the
HDAC-Sin3a corepressor complex or the
CoREST-HDAC complex (Denslow and
Wade, 2007). In 1998, four research
groups almost simultaneously character-ized the HDAC-containing Mi-2/NuRD
complex (Tong et al., 1998; Wade et al.,
1998; Xue et al., 1998; Zhang et al.,
1998). Mi-2a and Mi-2b proteins are also
known as CHD3 and CHD4 and are
large helicase-like ATPases containing
conserved PhD fingers, chromodomains,
and a putative DNA binding domain.
The human Mi-2 proteins, members of
the SWI/SNF superfamily, were initially
discovered as autoantigens in a connec-
tive tissue disease called dermatomyosi-
tis (DM). Of the DM patients, 25%
developed autoantibodies against Mi-2
and 20%–25% ultimately developed
malignant tumors in the ovary, lung,
pancreas, stomach, or colon, as well as
lymphoma, suggesting a link between
Mi-2/NuRD and carcinogenesis.
The broad use of the Mi-2/NuRD com-
plex in all tissues raises the question of
how this complex acquires tissue-specific
action. In a recently published paper in
Neuron, Yamada et al. (2014) studied
Mi-2/NuRD function in postmitotic neu-
rons, linking this complex to the develop-
ment of the synapse, which is essential for
the most important function of the brain,
neurotransmission.
The authors used immunoprecipitation
coupled with mass spectrometry to char-
acterize the NuRD complex in the devel-
oping cerebellum. By using RNAi against
four members of the NuRD complex
(Chd4, RbAp48, Hdac1, or Gatad2a/b)
via electroporation in postnatal rat pups
and Chd4 conditional knockout mice,
Yamada and colleagues found a profound
reduction in the density of presynaptic
parallel fiber boutons as well as reducedDevelopmental Csynaptic transmission in the cerebellar
cortex in vivo. Moreover, using RNA
sequencing, the authors uncovered
200 genes that are misregulated due
to Mi-2/NuRD deficiency, among which
>90% were upregulated and had in-
creased levels of promoter histone acety-
lation. Using a small interfering RNA-
based in vivo screening method, primarily
via an electrophoration technology devel-
oped in the Bonni laboratory for studying
cerebellar development, Yamada et al.
(2014) found three factors (nhlh1, elavl2,
and cplx3m) that, when knocked down,
led to enhanced synapse formation,
mimicking the function of Mi-2/NuRD
complex. Because both nhlh1 and elavl2
are downregulated during cerebellar syn-
aptogenesis and show reduced histone
acetylation, and because both promoters
are occupied by the Mi-2/NuRD complex,
the authors postulated that during synap-
togenesis of the cerebellum, Mi-2/NuRD
acts to shut down their expression
through direct binding and histone deace-
tylation, allowing for synaptogenesis to
proceed (Figure 1).
Among the genes screened by the
authors, only nhlh1, elavl2, and cplx3m
appeared to be involved in inhibition of
synaptogenesis; thus, it is likely that other
NuRD target genes might be involved in
other aspects of neuronal maturation.
Moreover, the regulation of cplx3m is
somewhat different from that of nhlh1
and elavl2 during cerebellar development
in that, unlike nhlh1 and elabl2, cplx3 is
not expressed in early developing cere-
bella, but its expression increases during
synaptogenesis. NuRD still appears toell 30, July 14, 2014 ª2014 Elsevier Inc. 9
Figure 1. Mi-2/NuRD Endows HDACs with Specificity in the Cerebellum
Inside the nucleus of cerebellar neurons, the Mi-2/NuRD complex serves to capture HDAC1/2 and target
them to specific genes including nhlh1 and elavl2, which in turn silences these genes, allowing for devel-
opment of presynaptic structures.
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Previewsact as a negative regulator for cplx3, but
perhaps not via direct binding to its
promoter. Clearly, genome-wide Chd4-
based chromatin immunoprecipitation
sequencing of the developing cerebellum
will be important to help unveil more
detailed modes of Mi-2/NuRD actions.
By analyzing the function of Mi-2/NuRD
in postmitotic neurons, Yamada et al.
(2014) uncovered a link between NuRD
and synaptogenesis. This finding could10 Developmental Cell 30, July 14, 2014 ª20have important implications for the
induced pluripotent stem cell (iPSC)-
based neurological disease modeling
field, which manipulates cells’ epigenetic
machinery to enhance iPSC-induction
efficiency. Indeed, the inhibition of the
Mi-2/NuRD complex has been found to
enhance reprogramming of somatic cells
into iPSCs (Kaji et al., 2006). Yamada
et al. (2014) caution that such manipula-
tions, while possibly affecting iPSC induc-14 Elsevier Inc.tion efficiency, would also hamper synap-
togenesis and potentially other functional
properties of the neurons, adding un-
wanted complications to the disease
modeling system.
Taken together, perhaps the most
important lesson to be learned by this
study is that while global-acting HDACs
appear to lack specificity, they can be
guided to regulate precise biological
processes through interactions with spe-
cific HDAC-containing complexes such
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